A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)
CONCLUSIONS: In this first prospective clinical trial of an anti-PD1 antibody for relapsed HM post-alloHCT, severe GVHD and irAEs occurred, even at the lower dose of nivo 0.5 mg/kg, leading to early closure due to toxicity. Modest anti-tumor activity was observed mainly in lymphoid malignancies known already to be responsive to anti-PD1 therapy, which may justify further exploration of anti-PD1 therapy in those populations in trials with strategies to mitigate toxicity; however, given the more favorable safety and efficacy profile of anti-CTLA-4 therapy in other HM, our future studies focus on combining ipilimumab with novel partners to improve outcomes.DisclosuresDavids: Celgene: Consultancy; MEI Pharma: Consultancy, Research Funding; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche/Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Consultancy; BMS: Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Dire...
Source: Blood - Category: Hematology Authors: Davids, M. S., Kim, H. T., Costello, C. L., Herrera, A. F., Locke, F. L., Maegawa, R. O., Savell, A., Mazzeo, M., Avigan, D. E., Chen, Y.-B., Nikiforow, S., Ho, V. T., Cutler, C. S., Alyea, E. P., Bachireddy, P., Wu, C. J., Streicher, H., Ball, E. D., Bas Tags: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Therapy of Post-Transplantation Relapse Source Type: research
More News: Accidents | Allergy & Immunology | AstraZeneca | Bilirubin | Cancer & Oncology | Clinical Trials | Genetics | Hematology | Hodgkin's Disease | Liver | Liver Transplant | Lymphoma | Merck | Non-Hodgkin's Lymphoma | Pharmaceuticals | Study | Toxicology | Transplants | Urology & Nephrology | Yervoy